Introduction
Multiple sclerosis (MS) is considered an autoimmune inflammatory demyelinating disease of the central nervous system (Furlan et al., 2009) . The instrumental role of CD4 + Th1 and Th17 myelin-reactive T cells in mediating disease pathology is well accepted. A role of B cells and antibody in the disease process is also acknowledged. A pathologic role for antibody is suggested by the correlation of oligoclonal bands in the CSF of MS patients with disease severity (Avasarala et al., 2001) . Furthermore, the importance of antibodies specific for conformational epitopes of myelin in the destruction of the myelin sheath is recognized (Brehm et al., 1999; Linington et al., 1988) . Clinical benefits upon B celldepletion support a role for B cells in the disease process (Hauser et al., 2008; Kappos et al., 2011; Naismith et al., 2010; Sorensen et al., 2014) , although the exact role of B cells and their products in MS pathogenesis is still unclear. Previous work from this group in the Experimental Autoimmune Encephalomyelitis (EAE) model of MS demonstrated that B cells and/or antibody were critical for the development of EAE when C57BL/6 (B6) mice were immunized with a recombinant form of human myelin oligodendrocyte glycoprotein (hrMOG) but not when immunized with the encephalitogenic peptide MOG35-55 (pMOG35-55) epitope (Lyons et al., 1999) . Our subsequent studies revealed that adding back either B cells or serum isolated from hrMOG-primed wild-type (WT) B6 mice was able to reconstitute disease in B cell-deficient (B cell −/− ) mice. MOG-specific serum was as effective, if not more effective, in reconstituting disease in B cell deficient mice than was adding back B cells. This suggested a role for an antigen-specific soluble factor in promoting hrMOG-induced disease in WT mice (Lyons et al., 2002) . However, the mechanism(s) by which B cells/antibody contribute to hrMOG-induced EAE remain under investigation.
Although our previous data demonstrated proliferative and cytokine responses to the encephalitogenic MOG35-55 epitope in hrMOG-immunized WT and B cell −/− mice, it is possible that additional epitopes are recognized in either the presence or absence of B cells or antibody that contribute to disease. We addressed this hypothesis using a panel of overlapping peptides spanning the extracellular portion of MOG, and discovered that T cells from hrMOG-immunized B cell −/− mice, but not WT mice, proliferated in response to MOG61-85. Subsequent experiments demonstrated that the MOG61-85 epitope inhibited disease initiation by the pMOG35-55 epitope.
Materials and methods

Mice
Female WT and B cell −/− B6 mice were purchased from Jackson Laboratory (Bar Harbor, ME) and immunized at 6-8 weeks of age. Mice were housed in specific pathogen free conditions according to NIH and University guidelines.
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